Overview
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.
Eligibility
Inclusion Criteria:
- pathologically or cytologically metastatic or locally advanced cancer
- anorexia and \>=5% weight loss during the past 6 months or anorexia with numerical scale of anorexia \>=5
- ECOG performance status 0-3
- able to complete questionaire and able to swallow pills
Exclusion Criteria:
- receiving chemotherapy or anti-cancer systemic therapy
- life expectancy longer than 1 month
- received radiotherapy at head/neck or thoracic or upper abdomen in the past 2 weeks
- surgery within 4 weeks
- pregnancy
- serum bilirubin \> 2 mg/dl or serum Cr \> 2 mg/dl
- current use of olanzapine or other antipsychotic drug
- known cardiac arrhythmia, uncontrolled brain metastasis, history of seizure or acute coronary event in the past 6 months
